Amgen Inc. (NASDAQ:AMGN) has been given an average recommendation of “Buy” by the twenty-two analysts that are currently covering the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $183.41.
Several analysts have weighed in on the stock. Leerink Swann reiterated a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Credit Suisse Group AG set a $206.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Saturday, September 17th. Vetr lowered shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $185.76 target price for the company. in a research note on Tuesday. Jefferies Group reiterated a “buy” rating and set a $187.00 target price on shares of Amgen in a research note on Wednesday, July 13th. Finally, Robert W. Baird reiterated a “neutral” rating and set a $157.00 target price on shares of Amgen in a research note on Friday, July 15th.
In related news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.20% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in AMGN. Eqis Capital Management Inc. increased its position in Amgen by 40.7% in the third quarter. Eqis Capital Management Inc. now owns 30,295 shares of the medical research company’s stock worth $5,054,000 after buying an additional 8,761 shares in the last quarter. West Oak Capital LLC increased its position in Amgen by 0.6% in the third quarter. West Oak Capital LLC now owns 10,262 shares of the medical research company’s stock worth $1,712,000 after buying an additional 65 shares in the last quarter. Beacon Financial Group increased its position in Amgen by 188.3% in the third quarter. Beacon Financial Group now owns 4,339 shares of the medical research company’s stock worth $718,000 after buying an additional 2,834 shares in the last quarter. Macquarie Group Ltd. increased its position in Amgen by 3.6% in the second quarter. Macquarie Group Ltd. now owns 105,159 shares of the medical research company’s stock worth $16,000,000 after buying an additional 3,625 shares in the last quarter. Finally, Carnick & Kubik Group LLC purchased a new position in Amgen during the second quarter worth approximately $2,307,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.
Shares of Amgen (NASDAQ:AMGN) opened at 167.55 on Friday. The company has a 50 day moving average of $171.31 and a 200 day moving average of $161.60. The firm has a market cap of $125.39 billion, a PE ratio of 17.15 and a beta of 0.94. Amgen has a 52 week low of $139.02 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. During the same quarter in the previous year, the firm earned $2.57 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen will post $11.36 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a yield of 2.39%. Amgen’s dividend payout ratio is currently 40.90%.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.